(주) 뷰노

Press Releases

VUNO Receives “A” Ratings in Technology Evaluations for IPO

  • 05. 29. 2020

VUNO Receives “A” Ratings in Technology Evaluations for IPO

VUNO Inc., South Korean artificial intelligence (AI) developer, announced that it received “A” ratings in the recent technology evaluations from the two assessment institutions, NICE D&B and Korea Enterprise Data, designated by the Korea Exchange (KRX) for the special listing of excellent technology companies on KOSDAQ, Korea’s secondary bourse. Based on the results, VUNO plans to submit a preliminary examination application soon.

VUNO’s AI solutions built upon its proprietary deep-learning engine, VUNO Net which optimizes the entire process of AI algorithm development, data preprocessing, and training, enables robust, device agnostic, and seamless integration and operation under any IT environments and devices. Now the company has unmatched technological capability to work with modalities encompassing medical imaging, pathology, biosignal, and speech, etc.

Beginning with VUNO Med®-BoneAge™, Korea’s first regulatory approved AI medical solution, VUNO’s other Med Series, ▷VUNO Med® - DeepBrain™, ▷VUNO Med® - Chest X-Ray™, ▷VUNO Med® – LungCT AI™, ▷VUNO Med® – Fundus AI™, and ▷VUNO Med® – Deep ASR™ are following suit with flying colors. Four of the solutions gained Korean regulatory approval and CE mark by proving its effectiveness through clinical tests carried out by large-scale medical institutions, attracting a lot of attention.

Hyun-Jun Kim, CEO of VUNO, explained that, “VUNO’s technological advancement in the AI field is demonstrated by this round of technology evaluation,” and added, “We will propel forth with the KOSDAQ listing process based on these results, while further making headway in increasing revenue from both local and global markets with our robust ongoing projects.

Contact Information

Yerim Kim / PR Manager, VUNO lnc.   
Email: rim@vuno.co

Tag in

#Press_Releases